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Abstract
The pathogenesis of canine inflammatory bowel disease (IBD) involves complex interactions
between mucosal immunity and the intestinal microbiota. Glucocorticoids are commonly
administered to reduce mucosal inflammation and gastrointestinal signs. The study objective
was to evaluate the effects of diet and oral prednisone on the spatial distribution of mucosal
bacteria in IBD dogs. Eight dogs diagnosed with IBD were treated with immunosuppressive
doses of prednisone. The mucosal microbiota from endoscopic biopsies of IBD dogs and
healthy controls (HC; n = 15 dogs) was evaluated by fluorescence in situ hybridization (FISH)
targeting the 16S rRNA genes of total bacteria and bacterial species relevant in canine/human
IBD. Apicaljunction protein (AJP) expression using immunohistochemistry investigated the
effect of medical therapy on intestinal barrier integrity. All IBD dogs had a reduction in GI signs
following diet and prednisone therapy compared with baseline CIBDAI scores (P < 0.05). The
mucosal microbiota of HC and diseased dogs was most abundant in free and adherent
mucus. Only Lactobacilli were increased (P < 0.05) in the adherent mucus of IBD dogs com-
pared to HC. The spatial distribution of mucosal bacteria was significantly different (P < 0.05)
in IBD dogs following prednisone therapy, with higher numbers of Bifidobacteria and Strepto-
cocci detected across all mucosal compartments and increased numbers of Bifidobacterium
spp., Faecalibacterium spp., and Streptococcus spp. present within adherent mucus. Differ-
ences in intestinal AJPs were detected with expression of occludin increased (P < 0.05) in IBD
dogs versus HC. The expressions of occludin and E-cadherin were increased but zonulin
decreased (P < 0.05 for each) in IBD dogs following prednisone therapy. In conclusion, the
spatial distribution of mucosal bacteria differs between IBD and HC dogs, and in response to
diet and glucocorticoid administration. Medical therapy was associated with beneficial changes
in microbial community structure and enhanced mucosal epithelial AJP expression.
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Introduction
Idiopathic inflammatory bowel disease (IBD) is a common chronic enteropathy in dogs char-
acterized by persistent or intermittent gastrointestinal (GI) signs and histopathologic inflam-
mation of the intestines.[1–3] While the exact etiologies for human IBD (i.e., Crohn’s disease
[CD] and ulcerative colitis [UC]) remain unknown, current evidence suggests that interactions
between the gut microenvironment (i.e., microbiota, dietary constituents), mucosal immunity
and host genetics initiate and drive chronic intestinal inflammation.[4, 5] Previous studies
have confirmed dysbiosis in the small and large intestines of dogs with IBD that is similar to
altered gut composition observed in human IBD.[6] These shared microbiome changes
include decreases in the phyla Firmicutes and Bacteroidetes with increases in Proteobacteria,
including the Enterobacteriaceae, observed in different studies.[7–9]
Therapeutic strategies for dogs with IBD generally include sequential therapy using spe-
cially formulated antigen-restricted diets, antimicrobials, and immunosuppressive drugs to
induce remission.[3, 10] In instances where affected dogs fail to respond to dietary and antimi-
crobial interventions, immunosuppressive drugs are often administered in the form of gluco-
corticoids (GCs), such as prednisone or prednisolone, being the mainstay of most treatment
regimens.[11, 12] The majority of effects of GCs are attributable to reduced expression of pro-
inflammatory and immune mediators, including cytokines (interleukin [IL]-1, IL-2, IL-6,
tumor necrosis factor-α [TNF-α]) and prostaglandins, which normally amplify intestinal
inflammation.[13] Whether or not GCs beneficially modulate the mucosal microbiota to help
reduce intestinal inflammation in dogs with IBD has not been systematically evaluated using
fluorescence in situ hybridization (FISH).
The objective of this study was to evaluate the effects of hydrolyzed diet and oral prednisone
on the spatial distribution of mucosal bacteria in dogs with IBD. We also characterized the
mucosal expression of tight junction proteins (TJPs) in relation to steroid therapy for induc-
tion of remission.
Materials and methods
Ethical animal use
Protocols for endoscopic collection of intestinal biopsies from healthy dogs and dogs with IBD
were approved by the Institutional Animal Care and Use Committee at Iowa State University
(IACUC Log numbers: 1-11-7061; 12-11-7269-K). Written informed consent was obtained
from all owners of enrolled dogs prior to tissue collection.
Animals
Two groups of animals were studied: dogs with IBD and healthy control (HC) dogs. The IBD
cohort presented with GI signs indicative of enterocolitis. Dogs with IBD (n = 8) were diag-
nosed according to stringent clinical criteria.[2] Enrollment criteria included: (i) a clinical his-
tory of intermittent or chronic GI signs of at least 3 weeks duration; (ii) failed response to
dietary (elimination diet fed exclusively for at least 3 weeks) and antimicrobial (metronidazole
and/or tylosin administered exclusively for 14 days) trials; (iii) failure to document other
causes for gastroenteritis through extensive diagnostic testing; and (iv) histopathologic evi-
dence of mucosal inflammation observed in endoscopic biopsies. Clinical disease activity at
diagnosis and in response to treatment was scored using the CIBDAI.[14] All IBD dogs were
enrolled during a short-term prospective clinical trial of approximately 1 year duration (2015–
2016).
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Following diagnosis of IBD, affected dogs were simultaneously placed on a hydrolyzed diet
(i.e., Purina HA Hydrolyzed or Royal Canin Canine Hydrolyzed Protein Adult HP to be fed
exclusively) and administered oral prednisone at a dosage of 1 mg/kg q12h for 3 weeks then
0.75–0.5- mg/kg q12h for 3 weeks then maintained or tapered over the following 2 weeks (total
treatment time = 8 weeks). All dogs with IBD were still receiving both diet and prednisone
therapy at the time of repeat GI endoscopy.
The HC group was comprised of 15 young adult dogs (< 3 years of age). None of the dogs
had exhibited GI signs for a period of at least 45 days prior to trial enrollment. Moreover, HC
dogs were judged to be healthy by one or more physical examinations and on the basis of nor-
mal results obtained on CBC and serum biochemical analysis, urinalysis, fecal parasite screens,
and dirofilarial antigen testing. All HC dogs were fed a commercial maintenance ration at the
time of GI endoscopy. Some of the HC dogs (n = 2) included in the present report were the
subject of a previous investigation.[9]
Endoscopic examination and intestinal biopsy collection
All HC and IBD dogs were subject to routine upper (gastroscopy/duodenoscopy) and lower
(ileoscopy/colonoscopy) GI endoscopy for collection of mucosal biopsy specimens. Dogs were
prepared for colonoscopy by withholding food overnight and administering an oral polyethyl-
ene glycol lavage solution (i.e., GoLYTELY), given twice at a dosage of 20 mL/kg, to evacuate
colonic contents. Prior to lower GI endoscopy, the endoscope and pinch biopsy forceps were
thoroughly cleaned and sterilized with an activated aldehyde solution and gas sterilization,
respectively. Multiple (12–15 mucosal samples from the duodenum; 5–7 mucosal samples
from the ileum; 10–12 mucosal samples from the colon) endoscopic biopsy specimens were
obtained and fixed in 10% neutral buffered formalin then paraffin embedded for histopathol-
ogy, using H&E stains, and for FISH. Colonic mucosal biopsies were obtained from each of
the ascending, transverse and descending regions, while ileal mucosal biopsies were obtained
along the distal 15 cm of this organ. All endoscopic examinations were performed by a single
operator (AEJ).
Histopathologic examinations were performed by a single pathologist (MA) blinded as to
each dog’s health status and clinical course. Mucosal biopsies were assessed for the presence of
mucosal inflammation using simplified WSAVA histopathologic guidelines.[15]
Immunohistochemical evaluation of apical junction proteins (AJPs)
The expression of AJPs was performed to assess intestinal epithelial barrier integrity associated
with dysbiosis at diagnosis and in response to diet and steroid administration. In brief, immu-
nohistochemistry for in situ expression of AJPs was performed on formalin-fixed colonic
biopsy specimens as previously described.[16] Paraffin-embedded tissue sections were rehy-
drated and neutralized for endogenous peroxidases with 3% hydrogen peroxide for 5 minutes
then rinsed for 5 minutes in distilled water. For antigen retrieval, slides were incubated in an
antigen retrieval solution of 0.01 M Tris-EDTA buffer (pH9.0) for claudin-2, occludin and E-
cadherin in a steamer (Black & Decker, Towson, MD, USA) for 20 minutes. For zonulin stain,
slides were immersed in a staining dish containing Sodium Citrate Buffer (10mM Sodium Cit-
rate, 0.05% Tween 20, pH 6.0) which was heated to 95–100˚C in a water bath and with the lid
placed loosely on the staining dish for an optimal incubation of 35 minutes. Following incuba-
tion, the slides were cooled for 20 minutes then washed in PBS-Tween 20 for 2x2 minutes. For
all tissue sections, non-specific binding was blocked by incubation with a protein-blocking
agent (Protein-blocking agent, Dako, Carpinteria, CA, USA) for 10 minutes before application
of the primary antibodies. Slides were incubated overnight in a moist-chamber (4˚C) with the
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following primary antibodies: Polyclonal rabbit anti-claudin-2 (Polyclonal rabbit anti-claudin-
2 (PAD: MH44), Invitrogen Ltd., Paisley, UK) and anti-occludin (anti-occludin PAD: Z-T22,
Invitrogen Ltd., Paisley, UK) antibodies and monoclonal mouse anti-E-cadherin IgG2α
(Monoclonal mouse anti-E-cadherin IgG2α (clone: 36), BD Biosciences, Oxford, UK) as
described previously.[16] For zonulin stain, the primary antibody was a rabbit derived poly-
clonal antibody (anti-Zonulin pAb, LS-C132998, LSBio Inc., USA, diluted 1:300). The immu-
nohistochemistry stain LS-C132998 pAb was validated previously using a panel of 21
formalin-fixed, paraffin-embedded (FFPE) human and canine tissues after heat-induced anti-
gen retrieval in pH 6.0 citrate buffer. Following incubation with the primary antibodies, slides
were incubated with biotinylated secondary antibodies. These antibodies included: 1) goat
anti-rabbit biotinylated immunoglobulin (E0432, Dako, Glostrup, Denmark) used at a dilution
of 1:250 and incubated for 1 hour to bind polyclonal rabbit-derived anti-zonulin, claudin-2
and occludin antibodies; and 2) goat polyclonal anti-mouse biotin-coupled secondary anti-
body (E 0443, Dako, Glostrup, Denmark) used at dilution of 1:200 and incubated for 1 hour to
bind monoclonal murine-derived anti-E-cadherin antibody. The incubation with secondary
antibodies was followed by an avidine-biotin complex (ABC elite, Vector, Burlingame, UK)
incubation of 45 minutes and a chromogen (DAB and Vector VIP, Vector) incubation of
approximately 10 minutes, but under direct microscope-control, evaluating the degree of
intensity of the stain.
To assess expression of claudin-2, occludin, E-cadherin, and zonulin proteins in endoscopic
biopsies obtained before and after diet and steroid treatment, stained tissue sections were eval-
uated at ×200 and ×630 (oil immersion) magnification to identify areas of consistent staining
and acceptable orientation. Immunostaining was evaluated along the length of multiple
enteric/colonic crypts and in areas of intact luminal epithelium. Stain intensity was subjec-
tively graded as adequate, and the localization and distribution of chromogen were noted. All
8 dogs with IBD and 10/15 control dogs were investigated for mucosal AJP expression.
All IHC positive cells were quantified using a light microscope (Carl Zeiss), a × 40 objective,
a × 10 eyepiece, and a square eyepiece reticule (10 × 10 squares, with a total area of 62,500
μm2). Ten appropriate sites were chosen for quantification and arithmetic means were calcu-
lated for each intestinal region. Results were expressed as the number of IHC positive cells per
62,500 μm2. The IHC stained slides were evaluated in a blinded manner by a single pathologist
(GR) to confirm staining specificity and to perform quantification of the number of AJP
expressing cells.
Fluorescence in situ hybridization (FISH)
Formalin-fixed ileal and colonic intestinal biopsy specimens (3 μM thick tissue sections) were
mounted on glass slides and evaluated by FISH as previously described.[17, 18] In brief, paraf-
fin-embedded tissue specimens were deparaffinized using an automated system by passage
through xylene (3 x 10 min), 100% alcohol (2 x 5 min), 95% ethanol (5 min), and finally 70%
ethanol (5 min). The slides were then transported in deionized water to the DNA testing labo-
ratory where they were air dried prior to hybridization. FISH probes 5’-labeled with either Cy-
3 or FITC (Life Sciences) were reconstituted with DNAse-free water and diluted to a working
concentration of 5 ng/μL (Table 1).
An Eub338 FITC-labeled probe was used for total bacteria counts. For other analyses, spe-
cific probes targeting Bifidobacteria, Faecalibacteria, Enterobacteriaceae, Lactobacilli, and
Streptococci were labeled with Cy-3 and were applied simultaneously with the universal bacte-
rial probe Eub338-FITC. This panel of probes was selected to identify specific bacterial groups
and individual bacterial species previously shown to be relevant in the pathogenesis of canine
Steroid effects on mucosal microbiota
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IBD.[8, 9] Tissue sections were bathed in 30 μL of DNA–probe mix in a hybridization chamber
maintained at 54˚C overnight (12 h). Washing was performed using a wash buffer (hybridiza-
tion buffer without SDS), the slides were rinsed with sterile water, then allowed to air-dry, and
mounted with SlowFade Gold mounting media (Life Technologies, Carlsbad, CA) and 25X25-
1 cover glass (Fisher Scientific, Pittsburgh, PA).
Probe specificity was confirmed in pilot studies by combining the irrelevant probe non-
Eub338-FITC with Eub338-Cy-3, and through hybridization experiments with pure isolates of
Bifidobacteria, Fecalibacteria, Enterobacteriaceae, Lactobacilli, and Streptococci to screen for
non-selective hybridization.
Quantification of intestinal mucosal bacteria
Intestinal bacteria were visualized by FISH and 4,6-diamidino-2-phenylindole (DAPI) staining
using a 60x Plan Apo oil objective in conjunction with an optional 1.5x multiplier lens on an
Eclipse TE2000-E fluorescence microscope (Nikon Instruments Inc., Melville NY) and photo-
graphed with a CoolSnap EZ camera (Photometrics, Tuscon, AZ) controlled by MetaMorph soft-
ware (Nashville, TN). Quantification was only performed when the hybridization signals were
strong and could clearly distinguish intact bacteria morphologically by either 2-color (universal
and bacterial-specific FISH probe) or 3-color (FISH probes and DAPI stain) identification.
A minimum of 4 different endoscopic biopsy specimens per dog (2 ileal and 2 ascending
and/or tranverse colonic biopsies) were evaluated for their mucosal bacterial content. Intestinal
tissues (endoscopic biopsies of ileum and colon) for FISH analysis were combined on glass
slides for ease of hybridization and consistency of interpretation by a single operator. In this
manner, a single slide would contain both ileal and colonic tissues (3–5 samples of each tissue)
in which the operator would perform 10 individual bacterial counts in separate endoscopic
specimens. While care was taken to accurately distinguish between ileal versus colonic mucosal
samples for quantitative analysis, a clear distinction between these tissues could not always be
determined. Therefore, mucosal bacterial counts for each animal were recorded as a cumulative
total of bacteria observed within ileal/colonic intestinal segments as previously described.[19]
Bacterial quantification was performed in 10 representative fields/dog at a final observed
magnification of 600x or 900x. The ten fields included bacteria found within 4 well-defined
mucosal compartments: (1) bacteria contained within the mucosa, (2) bacteria attached to the
surface epithelium, (3) bacteria localized within adherent mucus, and (4) bacteria found within
free mucus.
Statistical analysis
Sample size of enrolled IBD dogs was dictated by the length of time afforded to the prospective
clinical trial. During this period, other dogs (n = 6) were diagnosed with IBD but not enrolled
Table 1. FISH probe sequences.
Probe Sequence (5’! 3’) Target Reference
Eub338 GCT GCC TCC CGT AGG AGT Total bacteria Amann (1990)
Bif164 CAT CCG GCA TTA CCA CCC Bifidobacterium spp. Harmsen (2000)
Ebac1790 CGT GTT TGC ACA GTG CTG Enterobacteriaceae Poulsen (1994)
Faecali698 GTG CCC AGT AGG CCG CCT TC Faecalibacterium spp. Garcia-Mazcorro (2012)
Lab158 GGT ATT AGC ATC TGT TTC CA Lactobacillus spp. Harmsen (2000)
Strc493 GTT AGC CGT CCC TTT CTG G Streptococcus spp. Franks (1998)
https://doi.org/10.1371/journal.pone.0226780.t001
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due to failure to obtain informed client consent or the inability of clients to adhere to specific
treatment recommendations.
Mucosal bacteria in the control group (healthy dogs) were compared to the disease group
(dogs with IBD) using the Wilcoxon rank-sum (or Mann-Whitney) tests. Differences in bacte-
rial counts between pre- and post-prednisone treatment were assessed using the Wilcoxon
signed-rank test. For analysis of the number of cells expressing TJPs, Wilcoxon rank-sum and
paired two-sample t-tests were performed to investigate statistically significant differences
between healthy dogs and dogs with IBD before treatment, and between pre- and post- treat-
ment counts in IBD dogs, respectively. Data analyses were performed using R statistical soft-
ware (version 3.5.2; The R Foundation for Statistical Computing, Vienna, Austria). P-
values< 0.05 were considered as statistically significant.
Results
The clinical characteristics of study animals are shown in Table 2. The presenting clinical (gas-
trointestinal) signs, duration of illness, and severity of endoscopic and histopathologic lesions
observed in IBD dogs were similar to previous reports.[1–3, 10, 14, 15] Three dogs with IBD
had severe clinical disease activity (i.e., CIBDAI scores� 9) and 5 dogs with IBD had moderate
disease activity (i.e., CIBDAI scores 6–8) at the time of diagnosis (pre-treatment). All IBD dogs
had a reduction in GI signs following 8 weeks of diet and prednisone therapy compared with
baseline CIBDAI scores (P< 0.05). Clinical remission (defined as a�75% reduction in CIB-
DAI score from pre-treatment value [11]) was robust by post-treatment at Week 3 and was
sustained over the following 5 treatment weeks with tapering dosages of the drug. There was
no significant difference in severity of histopathologic scores of mucosal biopsies in IBD dogs
pre- versus post-treatment.
The mucosa-associated microbiota of healthy and diseased dogs was most abundant in free
and adherent mucus (Tables 3 and 4; S1 and S2 Tables). Sub-populations of bacteria hybrid-
ized with probes directed against Bifidobacterium spp., Faecalibacterium spp., Lactobacillus
spp., Enterobacteriaceae, and Streptococcus spp. There was no significant difference in the
number and spatial distribution of the different bacterial species within the mucosa (i.e.,
attaching to surface epithelia or invasive within tissues) for either HC dogs or dogs with IBD.
Table 2. Clinical characteristics of study animals.
Characteristic IBD dogs Controls
No. males/no. of females 5/3 0/15
Mean age (yr.) 5.2 2.1
Mean weight (kg.) 23.1 12.1
Mean CIBDAI scorea
Pre-treatment score 7.1 0
Post-treatment score 1.0 N/A
Disease duration (mo.) 7.7 0
Endoscopic lesionsb 100% None
Histopathologic lesionsc
Mild LPEC 3 None
Moderate-severe LPEC 5 None
a Clinical disease activity, range 0–18.
b Mucosal lesions of increased granularity, friability, and/or erosions visualized.
c Histopathologic severity of mucosal inflammation; LPEC = lymphocytic-plasmacytic enterocolitis.
https://doi.org/10.1371/journal.pone.0226780.t002
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Similarly, the total number of Eub338-positive bacteria was not significantly different at diag-
nosis or following medical treatment in dogs with IBD when compared to HC dogs. Only Lac-
tobacilli were increased (~8 fold, P< 0.05) in the adherent mucus of IBD dogs pre-treatment
compared to HC dogs. The spatial distribution of mucosal bacteria was significantly different
(P< 0.05) in IBD dogs following prednisone and dietary therapy, with higher numbers of Bifi-
dobacteria (~6 fold) and Streptococci (~5 fold) detected across all mucosal compartments and
increased numbers of Bifidobacterium spp. (~30 fold), Faecalibacterium spp. (~6 fold), and
Streptococcus spp. (~20 fold) present within adherent mucus (Figs 1 and 2).
The staining intensity and expression distribution of ileal and colonic AJPs was similar to
previous studies.[16, 19] The IHC labeling for all apical junction proteins was most intense
along the apical portion of epithelial cells in both ileal and colonic biopsies (Fig 3). Differences
in intestinal epithelial barrier proteins were observed with expression of AJP occludin
increased (~ 5 fold, P<0.05) in IBD dogs versus HC dogs. The expression of AJPs occludin
(~1.5 fold) and E-cadherin (~1.2 fold) was increased but the expression of zonulin decreased
(~3 fold, P< 0.05 for each) in IBD dogs following prednisone therapy. (Table 5; S3 Table).
Discussion
The mucosal microbiota in dogs with IBD treated with hydrolyzed diet and oral prednisone
for induction of remission was longitudinally investigated using FISH. This study is unique
because it compares the mucosal microflora in HC dogs to mucosal bacterial populations in
IBD dogs before and after diet and GC administration. We found that dogs with IBD had an
Table 3. Total bacteria via FISH (across all mucosal compartments).
Bacterial group Control dogs
Mean ± sd
IBD dogs pre-treatment
Mean ± sd
IBD dogs post-treatment
Mean ± sd
Bifidobacteria 28 ± 50 38 ± 49 240 ± 210a
Enterobacteriaceae 42 ± 82 148 ± 201 124 ± 131
Total bacteria 329 ± 263 500 ± 361 950 ± 771
Faecalibacteria 107 ± 119 121 ± 187 360 ± 330
Lactobacilli 16 ± 34 31 ± 42 41 ± 33
Streptococci 99 ± 121 87 ± 86 489 ± 486a
a Significant (P<0.05) difference between dogs with IBD pre- versus post-treatment.
https://doi.org/10.1371/journal.pone.0226780.t003
Table 4. Bacteria present via FISH in adherent mucus compartment.
Bacterial group Control dogs
Mean ± sd
IBD dogs pre-treatment
Mean ± sd
IBD dogs post-treatment
Mean ± sd
Bifidobacteria 4 ± 9 4 ± 6 121 ± 147a
Enterobacteriaceae 18 ± 59 22 ± 32 11 ± 6
Total bacteria 156 ± 139 118 ± 133 229 ± 174
Faecalibacteria 33 ± 28 23 ± 39 135 ± 177a
Lactobacilli 0 ± 2 8 ± 11b 7 ± 9
Streptococci 29 ± 35 12 ± 18 249 ± 398a
a Significant (P<0.05) difference between dogs with IBD pre- versus post-treatment.
b Significant (P<0.05) difference between control dogs and dogs with IBD pre-treatment.
https://doi.org/10.1371/journal.pone.0226780.t004
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increased number of Lactobacilli compared to HC dogs. Changes in the composition and spa-
tial distribution of mucosal bacteria were observed in IBD dogs post-GC and dietary treat-
ment, with more Bifidobacterium spp., Faecalibacterium spp. and Streptococcus spp. found
within the adherent mucus compartment. The mucosal expression of different epithelial AJPs
varied with increased levels of occludin and E-cadherin but decreased zonulin observed in
intestinal biopsies of IBD dogs following prednisone and dietary therapy.
Fig 1. Triple color FISH identifies mucosal bacteria in the adherent mucus compartment of dogs with IBD following prednisone and dietary therapy. Panels
A-C = ileal tissues and panels D-F = colonic tissues. Panel A = probe Cy3-Faecali698; Panel B = probe Cy3-Ebac; Panel C = probe Cy3- Strc493; Panel D = probe
Cy3-Bif164; Panel E = Cy3-Ebac; Panel F = probe FITC-Eub338. All other bacteria that hybridize exclusively with the universal probe (Eub338-FITC) appear green.
DAPI-stained intestinal mucosa with goblet cells appears blue. All images at 600x magnification.
https://doi.org/10.1371/journal.pone.0226780.g001
Steroid effects on mucosal microbiota
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There is an abundance of clinical evidence implicating alterations of the intestinal micro-
biota in the pathogenesis of IBD.[4, 6] Characteristic compositional changes in human IBD
patients include decreased microbial diversity with increased numbers of putative harmful
bacterial groups (the Enterobacteriaceae, including Escherichia coli [E. coli], and Fusobacter-
ium spp.) combined with decreases in protective species such as Lachnospiraceae, Bifidobacter-
ium spp., Roseburia, and Faecalibacterium prausnitzii.[5, 20, 21] There is very little data
describing the microbiome of companion animals with most data derived from the analysis of
Fig 2. Box plots showing total mucosal microbiota and microbiota in adherent mucus compartment of dogs with IBD before
and after prednisone and dietary therapy. Differences (P<0.05) in the numbers of bacteria between dog groups are indicated by red
asterisk.
https://doi.org/10.1371/journal.pone.0226780.g002
Fig 3. Immunohistochemical expression of AJPs in colonic biopsies of dogs with IBD after prednisone and dietary therapy. Protein expression
was defined on the basis of cell number and staining intensity of AJPs within the mucosa. Left panel = Claudin-2; center panel = E-cadherin; right
panel = occludin. See Table 3 for AJP comparisons between dog cohorts.
https://doi.org/10.1371/journal.pone.0226780.g003
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feces. The reported microbial shifts in dogs under disease conditions include lower abundance
of Fusobacteria, Bacteroidetes and Clostridiales, but a higher abundance of Proteobacteria in
duodenal cytobrushings and duodenal biopsy specimens.[7, 22] In separate studies, FISH tech-
niques have identified invasive E. coli in colon biopsies of dogs with granulomatous colitis [23,
24], and increased mucosal-associated Enterobacteriaceae (E. coli) in ileum/colon biopsies of
dogs with lymphocytic-plasmacytic enterocolitis [9, 19].
Canine chronic enteropathy non-responsive to diet and antimicrobial interventions are
designated as idiopathic IBD, which is confirmed by intestinal biopsy results showing mucosal
inflammation. In these instances, treatment typically requires immunosuppressive drugs, with
systemic GCs often used in most treatment regimens.[12] Separate randomized controlled tri-
als provide strong evidence for administration of oral GCs (i.e., prednisone, prednisolone and
budesonide) as induction therapy for dogs with IBD.[11, 25] Still other studies advocate a step-
up approach using prednisone first and then adding other immunosuppressive agents, as
needed, for non-responsive patients and those having severe clinical disease.[26] A similar
strategy is used in human IBD where systemic GCs are administered as first-line therapy for
remission induction of mild-moderate Crohn’s ileitis/colitis and severe ulcerative colitis.[27,
28]
It is widely accepted that glucocorticoids reduce mucosal inflammation via their general-
ized anti-inflammatory effects when administered systemically. Broadly, GCs activate many
anti-inflammatory genes (i.e., IκB-α [inhibitor of NF-κB], MKP-1 [inhibits MAP kinase path-
ways], and anti-inflammatory cytokines IL-10, IL-12) and suppress many pro-inflammatory
genes (i.e., IL-2, IL-6, IL-13, TNF-α as well as prostaglandins and leukotrienes) that are acti-
vated with inflammation.[13] Glucocorticoids also exert post-transcription effects to reduce
inflammation by promoting the rapid degradation of pro-inflammatory mRNA (i.e., mRNA
derived from TNF-α) and reduced inflammatory protein secretion.[29] Scientific studies
describing the effects of glucocorticoids on composition of the intestinal microbiota in healthy
animals are scarce. Steroid hormones can modify the composition of the fecal microbiota (pri-
marily the phyla Bacteroidetes and Firmicutes) in rodents following gonadectomy and in
response to hormone replacement.[30] Glucocorticoids (corticosterone implant) have also
been shown to modulate the fecal microbiome in wild birds by reducing potential pathogenic
avian bacteria and members of the Firmicutes.[31] Interestingly, oral administration of pred-
nisolone (1.0 mg/kg daily for 14 days) produced no effect on either bacterial diversity or com-
position of the fecal microbiota of healthy dogs.[32]
Still other investigations have evaluated the role of glucocorticoids in reshaping the intesti-
nal microbiota of chronic enterocolitis. Using a genetically-susceptible mouse model of colitis,
chronic (28 days) administration of dexamethasone was shown to alter fecal microbiota com-
position (i.e., increased Bifidobacterium spp. and Lactobacillus spp.) and promote the notable
Table 5. Number of intestinal epithelial cells expressing AJPs.
Apical junction protein Control dogs
Mean ± sd
IBD dogs pre-treatment
Mean ± sd
IBD dogs post-treatment
Mean ± sd
Claudin-2 1055 ± 75 783 ± 493 751 ± 454
E-cadherin 965 ± 230 1017 ± 602 1287 ± 366b
Occludin 181 ± 89 1098 ± 324a 1413 ± 399b
Zonulin 202 ± 127 371 ± 318 117 ± 60b
a Significant (P<0.05) difference between controls and dogs with IBD pre-treatment
b Significant (P<0.05) difference between dogs with IBD pre- versus post-treatment.
https://doi.org/10.1371/journal.pone.0226780.t005
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absence of Mucispirillum spp., a gut microbe reliant on mucin.[33] In one small prospective
randomized clinical trial, 19 children newly diagnosed with active CD were treated with either
enteral nutrition (EN) or corticosteroids (CS) for induction of remission. While both EN and
CS induced clinical remission following 8 weeks of continuous therapy, the EN-treated
patients showed a change in fecal microbiota composition to a higher proportion of Rumino-
coccus bacteria (with higher proportions of bacteria belonging to Clostridium spp.) as com-
pared to the CS-treated cohort.[34]
A single study has evaluated the intestinal mucosal microbiota in dogs with idiopathic IBD
or food-responsive diarrhea (FRD) before and after treatment.[35] Endoscopic biopsies of the
duodenum and colon were obtained from 24 dogs (15 FRD, 9 IBD) and evaluated by Illumina
sequencing of the bacterial 16S rRNA gene. Dogs with IBD were treated with elimination diet
and prednisolone (1 mg/kg BID) for 14 days. Results failed to reveal any significant differences
in the overall species richness of dogs with IBD versus FRD. When comparing the effect of
treatment on microbiota composition, the duodenum of dogs with FRD was enriched with
Enterococcus spp., Corynebacterium spp. and Proteobacteria pre-treatment, while Bacteroides
spp. was abundant in the colon of IBD dogs post-treatment.
Our results using FISH confirmed significant changes in the spatial distribution of select
mucosal bacteria (i.e., total bacteria and those bacterial sub-populations targeted by the 5 dif-
ferent oligonucleotide probes used in the present study) in dogs with IBD versus HC dogs, and
in IBD dogs receiving prednisone and dietary treatment. These data establish that glucocorti-
coids administered to dogs with IBD alter the distribution and composition of some of the
mucosal microbiota (i.e., increased numbers of Bifidobacteria, Faecalibacteria, and Strepto-
cocci) in adherent mucus of ileal and colonic tissues which may contribute to induction of
remission. The major limitations in the earlier canine study performed by others compared to
our report include: i) the absence of a healthy control dog group; ii) failure to describe criteria
of clinical remission and treatment group responses relative to changes in microbial composi-
tion; iii) failure to include ileal biopsies for microbial compositional analysis, and iv) the use of
16S rRNA gene sequencing which may identify broad shifts in community diversity but pro-
vides no information on microbial community structure as does FISH analysis.
It is clear that dysbiosis of the intestinal bacteria is both a cause and consequence of IBD. As
antibiotics and probiotics have only modest effects in managing patients with IBD[4], many
clinicians now opt for a top-down therapeutic approach using biologics and/or immunosup-
pressive drugs, such as glucocorticoids, to induce clinical remission[26, 36, 37]. Only few stud-
ies show that GCs (or any other immunosuppressive drug for that matter) can exert favorable
effects in the fecal microbiome (i.e., increased Clostridia, Bifidobacteria and Lactobacilli) of
IBD affected individuals. However, there are no studies (beyond the present report) which
describe how or why GCs selectively alter the mucosal microbiota in IBD. It is also possible
that other components of the gut microbiome (i.e., fungi and viruses) are influenced by GC
administration and contribute to beneficial modulation of resident bacterial populations as
observed in this study.[4]
The integrity of the intestinal epithelial barrier is critical for maintenance of mucosal
homeostasis. Recent experimental and clinical evidence indicates that apical junction proteins
(AJPs), including the tight junction proteins occludin, claudins, and ZO-1 and the adherens
junction protein, E-cadherin, provide crucial modulation of epithelial adhesion and intestinal
barrier function in IBD.[38] Reports in humans with IBD have demonstrated alterations in
AJP expression impacting both paracellular and channel functions of the epithelia.[39] Studies
show that claudin-2 abundance often increases in both CD [40] and UC [41] patients while the
expression of other barrier-forming claudins may be down-regulated [40, 42] in human IBD.
There are conflicts in the expression levels of AJPs in dogs with IBD. Some studies show
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increased expression of claudin-2 in colonic tissues at diagnosis [43] or in response to treat-
ment [16], while others report stable baseline occludin, zonulin, and E-cadherin expression
[43] or reduced occludin [16] expression in mucosal tissues following combination drug ther-
apy. Our results showed increased expression of AJP occludin in ileal/colonic biopsies of IBD
dogs pre-treatment versus HC dogs; with the mucosal expression of occludin and E-cadherin
increased but that of zonulin decreased in intestinal biopsies of dogs with IBD post-treatment.
There are some limitations in our study with the first being the small number of IBD dogs
enrolled in the trial. A larger cohort of diet and prednisone treated IBD dogs might have
yielded more obvious differences in microbial composition as compared to healthy dogs. Our
selection of probes used to identify mucosal bacteria was limited and may have missed changes
in other microbial community members affected by diet and GC administration. Second, gut
microbial populations may potentially vary by age, gender, breed, and dietary consumption.
Unfortunately, we were unable to match the age, breed, and sex of HC dogs to dogs with IBD.
Also, HC dogs were fed a different (maintenance) ration as compared to the hydrolyzed diet
fed to dogs with IBD. It is possible that the varying proportions of dietary constituents (i.e.,
protein source and content, % fat, etc.) contained in the maintenance and hydrolyzed rations
also influenced gut bacterial populations. However, our own studies, evaluating the potential
impact of age, body weight, and/or diet, have not identified any associations of microbial
abundances with these variables in dogs previously.[9, 44]
In conclusion, the spatial distribution of select mucosal bacteria differs between IBD dogs
and HC dogs and in response to diet and glucocorticoid administration. Oral prednisone and
dietary therapy were associated with potential beneficial changes in microbial community
structure (i.e., increased numbers of Bifidobacterium spp., Faecalibacterium spp., and Strepto-
coccus spp.) and enhanced mucosal epithelial AJP expression, indicating increased epithelial
barrier function. Analysis of intestinal microbiota using FISH provides valuable insights on
the abundance and spatial distribution of mucosal bacteria which interact most closely with
the intestinal epithelium.
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